Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureRebecca A. Taub, Robin Mogg, Dominic Labriola, Raul C. Camacho, Quentin Mark Anstee
Abstract
Authors
Institutions
No local reference links have been materialized yet.
No local citing links have been materialized yet.
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
10.1097/hep.0000000000000520 · 2023
Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis
10.1056/nejmra1503519 · 2017
Nonalcoholic Fatty Liver Disease and the Heart: JACC State-of-the-Art Review
10.1016/j.jacc.2018.11.050 · 2019
Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease
10.1053/j.gastro.2015.04.043 · 2015
Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis
10.1002/hep.29085 · 2017
Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD
10.1016/j.jhep.2017.07.027 · 2017
NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances
10.1038/s41395-018-0088-6 · 2018
Burden of Illness and Economic Model for Patients With Nonalcoholic Steatohepatitis in the United States
10.1002/hep.30254 · 2019
Estimated Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease in US Adults, 2020 to 2050
Provenance
crossref
Confidence 100%
ror
Confidence 99%
ror
Confidence 99%
ror
Confidence 99%
pubmed
Confidence 98%
unpaywall
Confidence 95%
openalex
Confidence 95%
datacite
Confidence 0%
10.1001/jamanetworkopen.2024.54707 · 2025
Toward Genetic Prediction of Nonalcoholic Fatty Liver Disease Trajectories: PNPLA3 and Beyond
10.1053/j.gastro.2020.01.053 · 2020
Genetic and epigenetic factors determining NAFLD risk
10.1016/j.molmet.2020.101111 · 2021
Therapeutic opportunities for the treatment of NASH with genetically validated targets
10.1016/j.jhep.2023.05.007 · 2023
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
10.1038/ng.257 · 2008
Pi*Z heterozygous alpha-1 antitrypsin states accelerate parenchymal but not biliary cirrhosis
10.1097/meg.0000000000000061 · 2014
Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease
10.1038/ng.2901 · 2014
The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent
10.1053/j.gastro.2016.01.032 · 2016
A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease
10.1056/nejmoa1712191 · 2018
A missense variant in Mitochondrial Amidoxime Reducing Component 1 gene and protection against liver disease
10.1371/journal.pgen.1008629 · 2020
A genome-first approach to mortality and metabolic phenotypes in MTARC1 p.Ala165Thr (rs2642438) heterozygotes and homozygotes
10.1016/j.medj.2021.04.011 · 2021
Selective Thyroid Hormone Receptor-Beta (TRbeta) Agonists: New Perspectives for the Treatment of Metabolic and Neurodegenerative Disorders
10.3389/fmed.2020.00331 · 2020
Thyroid Hormone Mediated Modulation of Energy Expenditure
10.3390/ijms160716158 · 2015
Thyroid Hormone Decreases Hepatic Steatosis, Inflammation, and Fibrosis in a Dietary Mouse Model of Nonalcoholic Steatohepatitis
10.1089/thy.2021.0621 · 2022
10.1021/jm4019299
10.1021/jm4019299 · 2014
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
10.1056/nejmoa2309000 · 2024
Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-beta agonist
10.1016/j.atherosclerosis.2013.07.056 · 2013
Resmetirom (MGL-3196) in Patients With Heterozygous Familial Hypercholesterolemia
10.1016/j.jacc.2022.01.023 · 2022
Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial
10.1038/s41591-023-02603-1 · 2023
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
10.1016/s0140-6736(19)32517-6 · 2019
Patatin-Like Phospholipase Domain-Containing Protein 3 I148M and Liver Fat and Fibrosis Scores Predict Liver Disease Mortality in the U.S. Population
10.1002/hep.31032 · 2020
PNPLA3 Genotype and Risk of Liver and All-Cause Mortality
10.1002/hep.31113 · 2020
Combined Effect of PNPLA3, TM6SF2, and HSD17B13 Variants on Risk of Cirrhosis and Hepatocellular Carcinoma in the General Population
10.1002/hep.31238 · 2020
Association of HSD17B13 rs72613567:TA with non-alcoholic fatty liver disease in Hispanics/Latinos
10.1111/liv.14387 · 2020
Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation
10.1111/j.1464-5491.2006.01858.x · 2006
Distinct contributions of metabolic dysfunction and genetic risk factors in the pathogenesis of non-alcoholic fatty liver disease
10.1016/j.jhep.2021.10.013 · 2022
Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease
10.1002/hep.24283 · 2011
Association between patatin-like phospholipase domain containing 3 gene (PNPLA3) polymorphisms and nonalcoholic fatty liver disease: a HuGE review and meta-analysis
10.1038/srep09284 · 2015
The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease
10.1002/hep.23759 · 2010
Splice variant rs72613567 prevents worst histologic outcomes in patients with nonalcoholic fatty liver disease
10.1194/jlr.p089953 · 2019
TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease
10.1038/ncomms5309 · 2014
Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease
10.1002/hep.27490 · 2015
Quantitative regression of qFibrosis with resmetirom: Exploratory histologic endpoints from the MAESTRO-NASH phase III clinical trial
10.1016/j.jhep.2026.03.021 · doi-reference
Consistent efficacy of efruxifermin across PNPLA3 genotypes in phase 2b trials in MASH
10.1097/hep.0000000000001792 · doi-reference
PNPLA3(148M) is a gain-of-function mutation that promotes hepatic steatosis by inhibiting ATGL-mediated triglyceride hydrolysis
10.1016/j.jhep.2024.10.048 · doi-reference
Nonalcoholic Fatty Liver Disease and Hypercholesterolemia: Roles of Thyroid Hormones, Metabolites, and Agonists
10.1089/thy.2018.0664 · doi-reference
TM6SF2/PNPLA3/MBOAT7 Loss-of-Function Genetic Variants Impact on NAFLD Development and Progression Both in Patients and in In Vitro Models
10.1016/j.jcmgh.2021.11.007 · doi-reference
Effects of Resmetirom on Metabolic-Dysfunction Associated Steatohepatitis in Patients With Weight Loss and/or Diabetes Taking Glucagon-Like Peptide-1 Receptor Agonists and Other Diabetes Therapies: A Secondary Analysis of the MAESTRO-NASH Trial
10.1111/apt.70382 · doi-reference